Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis

Clinical Infectious Diseases

Volumn 62, Issue 7, 2016, Pages 829-836

  Eberhardt, Christiane S ^a   Blanchard Rohner, Geraldine ^a   Lemaître, Barbara ^a   Boukrid, Meriem ^a   Combescure, Christophe ^a   Othenin Girard, Véronique ^a   Chilin, Antonina ^a   Petre, Jean ^b   De Tejada, Begoña Martinez ^a   Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b BioNet Asia   (Thailand)

Author keywords

maternal antibodies; maternal immunization; neonates; pertussis; pregnancy

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; MATERNAL ANTIBODY; PERTUSSIS TOXIN; BACTERIUM ANTIBODY; PERTUSSIS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PASSIVE IMMUNIZATION; PERTUSSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VACCINATION; BLOOD; BORDETELLA PERTUSSIS; IMMUNIZATION; IMMUNOLOGY; INFANT, NEWBORN, DISEASES; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; WHOOPING COUGH;

ADULT; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PERTUSSIS VACCINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; TIME FACTORS; WHOOPING COUGH;

EID: 84963959687     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw027     Document Type: Article

References (38)

1. Jakinovich A, Sood SK. Pertussis: still a cause of death, seven decades into vaccination. Curr Opin Pediatr. 2014; 26: 597-604.
2. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr. 2012; 161: 1091-6.
3. Health Protection Agency. Confirmed pertussis in England and Wales: data to end-December 2012. Health Protection Report, 2013; 7.
4. Centers for Disease Control and Prevention. Pertussis outbreak trends. Available at: http://www.cdc.gov/pertussis/outbreaks/trends.html. Accessed 1 November 2015.
5. Tiwari TS, Baughman AL, Clark TA. First pertussis vaccine dose and prevention of infant mortality. Pediatrics. 2015; 135: 990-9.
6. Forsyth K, Plotkin S, Tan T, Wirsing von Konig CH. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015; 135: e1475-82.
7. Urwyler P, Heininger U. Protecting newborns from pertussis-The challenge of complete cocooning. BMC Infect Dis. 2014; 14: 397.
8. Halasa NB, OShea A, Shi JR, LaFleur BJ, Edwards KM. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr. 2008; 153: 327-32.
9. Knuf M, Schmitt HJ, Jacquet JM, et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr. 2010; 156: 675-8.
10. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008; 152: 655-60, 660.e1.
11. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheriapertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011; 204: 334.e1-5.
12. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013; 32: 1257-60.
13. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013; 56: 539-44.
14. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged 12 months Advisory Committee on Immunization Practices (ACIP 2011 MMWR Morb Mortal Wkly Rep. 2011 60 1424-6.
15. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 131-5.
16. UK Department of Health. Pregnant women to be offered whooping cough vaccination. Available at: http://www.dh.gov.uk/health/2012/09/whooping-cough/. Accessed 1 November 2015.
17. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014; 384: 1521-8.
18. Dabrera G, Amirthalingam G, Andrews N, et al A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis. 2015; 60: 333-7.
19. Office Fédéral de la Santé Publique. Adaptation des recommandations de vaccination contre la coqueluche: pour les adolescents, les nourrissons fréquentant une structure daccueil collectif et les femmes enceintes. Bull OFSP. 2013; 9: 118-23.
20. Seubert A, DOro U, Scarselli M, Pizza M. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. Expert Rev Vaccines. 2014; 13: 1191-204.
21. Buasri W, Impoolsup A, Boonchird C, et al. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated pertussis toxin and pertactin by unmarked allelic exchange. BMC Microbiol. 2012; 12: 61.
22. Rohner GB, Meier S, Bel M, et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenzaspecific antibodies to the newborn. Pediatr Infect Dis J. 2013; 32: 1374-80.
23. Roduit C, Bozzotti P, Mielcarek N, et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun. 2002; 70: 3521-8.
24. Largo RH, Pfister D, Molinari L, Kundu S, Lipp A, Duc G. Significance of prenatal, perinatal and postnatal factors in the development of AGA preterm infants at five to seven years. Dev Med Child Neurol. 1989; 31: 440-56.
25. Cherry JD, Gornbein J, Heininger U, Stehr K A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998; 16: 1901-6.
26. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990; 161: 487-92.
27. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J. 2011; 30: 608-10.
28. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014; 311: 1760-9.
29. Heininger U, Riffelmann M, Bar G, Rudin C, von Konig CH. The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J. 2013; 32: 695-8.
30. Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol. 2001; 13: 993-1002.
31. Ercan TE, Sonmez C, Vural M, Erginoz E, Torunoglu MA, Perk Y. Seroprevalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine. 2013; 31: 4172-6.
32. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004; 190: 335-40.
33. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012; 2012: 985646.
34. van den Berg JP, Westerbeek EA, Berbers GA, van Gageldonk PG, van der Klis FR, van Elburg RM. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, Haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J. 2010; 29: 801-5.
35. Heininger U, Riffelmann M, Leineweber B, Wirsing von Koenig CH. Maternally derived antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin in preterm and full term newborns. Pediatr Infect Dis J. 2009; 28: 443-5.
36. Abu Raya B, Srugo I, Kessel A, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels-A prospective study. Vaccine. 2014; 32: 5787-93.
37. Murray GD. Switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001; 52: 219.
38. US Food and Drug Administration. Guidance for industry-non-inferiority clinical trials. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@ fdagov-drugs-gen/documents/document/ucm202140.pdf. Accessed 1 November 2015.